drugset / Trial / NCT01329042

Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis

NCT01329042

RandomizedParallel-groupOpen-labelTreatment

Summary

Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone. Although providing good results, stone recurrence is usually found as the therapies do not change the underlying metabolic abnormality. Among the metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis. This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.

Timeline

Start
2005-05
Primary completion
2007-10
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject POTASSIUM SODIUM HYDROGEN CITRATE ANHYDROUS Small molecule 81 meq Oral